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OBJECTIVE: 
An observational study to compare the incidence of Ventilator Associated Pneumonia in 
patients intubated with standard E.T tube ETT C vs. ETT SS Subglottic suction drainage 
tube in ICU. 
METHODS: 
Adult patients admitted to intensive care unit (ICU) with duration of artificial respiration 
>48 hrs. were included in this study. The type of ET tube used for intubation was 
noted. Surveillance for Ventilator Associated Pneumonia in this study was in accordance with the 
latest “Surveillance for ventilator-associated events in the National Healthcare Safety Network 
(NHSN)” guidelines released in Jan 2014. Variables like Patient details, diagnosis, pre-existing illness, 
APACHE II, number of days on ventilator, number of days of ICU & hospital stay and 
hospital mortality were noted in both groups. 
 
RESULTS: 
In total 88 patients were enrolled in the study, 43 in ETT SS group and 45 in ETT C 
group. The incidence of VAP in our ICU was 4.24 per 1000 ventilator days. The incidence of VAP was 
lower in ETT SS (0 %) compared with ETT C group (4.44%) though, were not statistically significant 
because of the small incidence. The overall incidence of VAE- Ventilator associated events 
(VAC+IVAC+POSSIBLE VAP+PROBABLE VAP) when both groups combined 
Was 16.94 per 1000 ventilator days. The incidence of VAE between the two groups were 
similar as there were 5 (11.6 %) VAE in ETT SS group vs. 3 (6.6 %)  
CONCLUSION: 
The incidence of VAP in ICU showed a reduced trend with the use of ETT SS in comparison with 
ETT C.  
INTRODUCTION
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HAIS AND VENTILATOR ASSOCIATED PNEUMONIA
HAIs (HAI) are so prevalent nowadays all around the world.
Today it presents a considerable challenge in healthcare, as it appreciably 
increases the morbidity and mortality of patients, increases the duration of hospital stay, 
leads often the usage of broad spectrum antibiotics etc. This ultimately translates into 
higher spending than anticipated.  
Especially in our country where the awareness regarding preventive measures for 
HAI is limited, the financial burden to the patients and their families due this 
complication is huge.
 For patients who are critically ill and with poor respiratory function and those 
who undergo long duration surgeries, mechanical ventilation is an important and life 
saving intervention.  These patients can develop complications like,
  Ventilator-associated pneumonia.
 Septicemia
 Acute Respiratory Distress Syndrome.
 Barotrauma
 Pulmonary embolism, 
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 Pulmonary edema, etc.
The above mentioned statuses can lead to increased,
 Duration of mechanical ventilation,
  ICU and hospital stay
  Healthcare costs, and 
 Risk of morbidity and mortality.
Among the complications mentioned earlier, Ventilator associated pneumonia or 
VAP is one of the common HAI, associated with increased morbidity and death  in ICU 
s(1). 
Studies have demonstrated that the risk of HAI in ICU ranges from 8% to 25%, 
with an incidence of 5 to 10 cases per 1000 ventilator-days (2,3). 
VAP alone can result in requirement of
 broad spectrum antibiotic usage, 
 prolongation of ventilatory days, 
 increase in duration of  ICU stay, 
 increased duration of stay in hospital,
  increased mortality & morbidity and 
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 increase in cost of treatment 9.  
Multiple preventive measures are used to prevent this complication; the current 
recommendations (6) are, 
1.  Head end elevation of the cot by 30-40 degrees,
2.  Strict cuff pressure maintenance in the E.T. tube (20-25) cm H20
3.  Oral hygiene
4.  Circuit changes at regular intervals or when soiled with secretion ,
5.  Using heated humidifiers and HMEs (heat and moisture exchanger) ,
6.  Providing oral care with chlorhexidine and water-soluble mouth moisturizer ,
7. Use of specially designed E.T. tube for removing secretions, 
8. Use of Closed- in-line suction,
9.  Assessment for kinetic bed therapy
10.  Employing sedation holiday
11.  Appraisal of weaning readiness with spontaneous breathing trials 
whenever feasible
12.  Stress related gastric ulcer prophylaxis and
13.  DVT prevention strategies.     
  One of the postulated causes of ventilator associated pneumonia (VAP) is micro-
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aspiration of subglottic secretions.
 Among several factors, micro aspiration of these oral secretions, which pool in the
laryngopharynx above the cuff of endotracheal tube leads to VAP. 
Standard endotracheal tubes (ETT C) do not have an option to remove these 
secretions. But, newer endotracheal tubes with a dedicated suction port just above the 
cuff (ETT SS) are available these days. 
This new design of endotracheal tube (ETT SS), which has facility to aspirate the 
subglottic secretions through an additional port intermittently or continuously.
Some studies have shown a reduction in Ventilator Associated Pneumonia when 
ETT SS was used . This has not been studied in our institution.
Some other earlier studies have not shown definitive benefit for the clearance of 
subglottic secretions in reducing the incidence of Ventilator Associated Pneumonia (2,7–
13), therefore requiring further research to support this intervention.
 In our study we hypothesize the use of ETT SS will decrease the incidence of 
Ventilator Associated Pneumonia.
In addition the surveillance in the past were less clear for Ventilator Associated 
Pneumonia as earlier definition(s) of Ventilator Associated Pneumonia was less 
objective with parameters like chest x-ray which is very subjective. 
To make surveillance more objective, Centers for Disease Control and Prevention 
released a set of recommendations in January 2014.
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 This recommendation is based on objective, efficient, and possibly automatable 
criteria that will deliberately identify a wide range of conditions and complications 
happening in mechanically ventilated patients. 
There are three definition levels within the ventilator associated event (VAE) 
algorithm: (14) 
1) Ventilator Associated Condition (VAC); 
2) Infection related Ventilator Associated Complication (IVAC); and 
3) Possible and Probable Ventilator Associated Pneumonia. 
The above definitions are described in detail  later. 
As a standard practice ETT SS is used for all intubations performed in our ICU. 
Patients intubated outside our ICU (who are subsequently transferred to our ICU for 
ventilation) for example in the Accident and Emergency Department, Operation Theaters
etc are intubated with ETT C. 
Therefore, we decided to do a research to find out whether the usage of ETT SS in
our Intensive Care Units does impact the incidence of Ventilator Associated Pneumonia 
or not.
And also we decided to use the latest VAP surveillance algorithm released by 
CDC in January 2014 for our research.  
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AIM OF THE RESEARCH
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AIM:
To compare the incidence of Ventilator Associated Pneumonia in patients 
intubated with standard E.T tube ETT C vs ETT SS ie. Subglottic suction drainage
tube in the intensive care unit.
18
OBJECTIVES OF THE RESEARCH
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OBJECTIVES OF THE RESEARCH:
1) To study the incidence of Ventilator Associated Pneumonia in both group of 
patients in general,
2) To study the incidence of Ventilator Associated Events in particular
such as,
a)  Ventilator Associated Condition (VAC)
b)  Infection related Ventilator Associated Complication (IVAC)
c)  Possible Ventilator Associated Pneumonia and
d)  Probable Ventilator Associated Pneumonia. 
3)  To study  the 
a) duration of mechanical ventilation , 
b) duration of ICU stay and 
c) duration hospital stay in both the groups
4) To find the in hospital mortality in both groups of patients.
20
REVIEW OF LITERATURE
21
HAIS
World Health Organization defines HAI  as,
“An infection acquired in hospital by a patient who was admitted for a reason 
other than that infection. An infection occurring in a patient in a hospital or other 
health care facility in whom the infection was not present or incubating at the time of 
admission. This includes infections acquired in the hospital but appearing after 
discharge, and also occupational infections among staff of the facility.”(1)
HAIs like
  surgical site/wound infection, 
  infection of urinary tract and
  respiratory infections. 
are a major cause of morbidity and mortality not only in developed countries but also in 
developing countries like India.(1–3)
One of the  highest prevalence of HAI happens in ICUs.(1)
Especially device related infections such as
 Ventilator-associated pneumonia ,
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 Central venous catheter related infections  and 
 Catheter related urinary tract infections 
    pose a big threat to patient safety in the Intensive Care Unit .(2) 
There are a few studies done till now estimating increased spending as a result of 
HAI or Hospital acquired infections in our country. In India, health insurance coverage 
among our population is said to be less than 15% or less. Health related payments are 
managed primarily out-of-pocket in our country and this sort of payment is  
comparatively among the highest in the world.(3) 
Thus, nosocomial infections has serious implications on the Indian patient 
creating additional burden of costs and suffering.
So, the issue of HAI hospital acquired infections need to addressed 
comprehensively enabling an optimized and efficient health care planning, organisation 
and implementation.(1–3)
In some studies, hospital-acquired infection HAI rates is about 1% in the 
developed countries and in the other extreme more than 40% in developing countries in 
certain parts of Asia, Latin America and Africa.(3)
The above mentioned data reflects the huge burden posed by HAIs in poorer 
countries where the economic reserve of an individual patient as well as of these 
governments as a whole is limited and unequally distributed.(3)
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In our country for example where one sixth of the world's population reside, the 
additional burden of costs attributable to these infections has serious inferences such as  
emotional stress and disabling conditions that reduces the quality of life..
 Therefore, warranting strict adherence to known HAI  preventive measures and constant
need for continued research, surveillance and accountability.
In-spite of huge (often unequal) progress in public health-care in our country, 
infections continue in hospitalised patients even putting healthcare personnel at risk of 
infection.(2,3)
The main  factors that promote infection among hospitalised patients are(1,2),
 Extremes of age— neonates, infants, and elderly people,
 lesser immunity among patients,
 Length of hospital stay
 Catheters in situ and invasive medical procedures,
 invasive techniques and interventions creating potential routes of infection,
 Unjustified antibiotic usage and the spread of drug-resistant pathogens ,
24
 Use of antacids in ulcer prevention,
 Mechanical ventilation,
 Use of total parenteral nutrition,
 lack and of strict adherence to infection control practices .
25
PREVENTIVE MEASURES FOR NOSOCOMIAL INFECTIONS
The folowing are the recommended preventive measures for HAI,
26
1) Hand washing(4):
 as often as possible especially before and after touching patients and their 
associated equipments , articles etc.
 use of alcoholic hand spray because it acts rapidly, more efficient and minimal 
time commitment, allows easy and complete compliance.
 removing jewelery before washing hands.
 Continuous monitoring and education to encourage hand washing. 
2) Cleaning stethoscopes, ultrasound probes, monitoring aids, oxygen masks etc. 
between patients and usage of barrier covers.
3)Gloves(4): as an accessory to hand washing
4)In case of invasive line insertions(4)s:
 strict aseptic precaution and use of alcoholic chlorhexidine or 70% isopropyl 
alcohol for at least 30 seconds and should be allowed to dry before inserting 
the cannula. 
 changing i.v.  sets every 3 days.
 use of a clear, adhesive, polyurethane dressings (Tegaderm) which are more
permeable instead of standard dressing to reduce moisture accumulation and 
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infection rates.(4)
5) Strict adherence Ventilator Associated  Pneumonia bundle in ventilated patients for   
ventilator associated pneumonia prophylaxis. (5,6)
6)Use of mask, gown even-though the evidence is conflicting should be at least done for 
invasive procedures.
7) Avoidance of white coat and use of disposable aprons for close contact examinations, 
dressings etc.(4)
8)Continued surveillance pro-grammes for accountability of infection control practices 
and its effectiveness.(7)
8)Continued education and creating awareness regarding nosocomial infections and  
preventive strategies among health care personnel and the hospital population.(2,4,7)
 Despite the awareness and the various preventive measures   nosocomial infections  
continue to  haunt  our hospitals especially our ICUs. It is the most common nosocomial 
infection in patients who are mechanically ventilated in the critical care units (ICUs).
(8,9)
Also, VAP is the 2nd commonest  HAI  in critical care units contributing to about 50 % of all
cases of  hospital-acquired pneumonia.(8,9)
Therefore, we decided to do a research to find out the incidence ofVAP- ventilator
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associated pneumonia, the commonly acquired nosocomial infection in our ICU.
By the end of this research we will know whether the  Ventilator Associated 
Pneumonia bundle plus the use of specially designed endotracheal tubes makes a 
significant impact in its prevention.
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VENTILATOR ASSOCIATED PNEUMONIA (VAP)
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INTRODUCTION:
As we come across the literature, the definition for Ventilator Associated 
Pneumonia or VAP keeps changing over time but controversy does not, and the 
definition given below will be one of the most acceptable one. 
“Ventilator Associated Pneumonia (VAP) is defined as pneumonia occurring in a 
patient within 48-72 hours or more after intubation with an  invasive airway 
(endotracheal tube or tracheotomy tube) and which was not present earlier”.
Which is defined by the presence of 
 a new or progressive patchy infiltrate on chest radiography, 
 signs of systemic infection like hypothermia or febrility, 
 abnormal  WBC count Leucocytosis > 12000WCC/uL or leucopenia <4000 
WCC /uL, 
 changes in color/character of sputum or endo-tracheal aspirate , and
 detection of an infective agent by  microbiology .
It is the commonest  nosocomial infection in patients who are mechanically 
ventilated in the critical care units (ICUs).
As we said earlier, VAP is the 2nd commonest nosocomial infection in the critical 
care unit contributing to about half of all cases of hospital-acquired infections. 
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Especially in mechanically ventilated patients incidence ventilator associated pneumonia
is is about 9–27 %, with the higher risk during early period of hospitalization.(8,9)
 Considerable investigation efforts were made in the last decade in the field 
of the  of ventilator-associated pneumonia and its management. Previous scrutinies have 
provided important knowledge regarding the histology and bacteriology concerning 
ventilator associated pneumonia ,which is important  to later research.
Various earlier epidemiological studies have established new concepts for 
empirical initial antibiotic treatment for ventilator associated pneumonia that are 
expected to improve clinical outcomes. Over the years, crucial developments have been 
made regarding ventilator associated pneumonia prevention. (10)
Having said that, most of the issues concerning the diagnosis and treatment of 
ventilator associated pneumonia remains unsettled and contention exists till date. 
There is no consensus in diagnostic evaluation of ventilator-associated pneumonia
and that partly explains why incidence of ventilator associated pneumonia rates vary 
widely in different studies. (7–10)
 And it was apparent we came across earlier studies, they place the risk of death 
for Ventilator Associated Pneumonia at between 5–50 % almost (doubling mortality in 
some studies). But this proportion is variable and depends to a great extent on the 
underlying medical ill health.(8–10)
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In recent years, the attributable risk of mortality has decreased to about ( 9–13 %) 
mainly because of implementation of Ventilator Associated Pneumonia preventive 
strategies.(8,9,11)
In our hospital which is a tertiary care referral center we continue to face the 
problem of ventilator associated pneumonia and despite having a hospital infection 
control committee (HICC) which surveys the annual incidence of all hospital acquired 
infection HAIs.
According to hospital infection control committee's (HICC) recent surveillance 
the incidence of VAP in all our  ICUs put together is about 40% in the previous year.
In the coming sections we shall discuss in detail about,
1. THE ETIOLOGY OF VENTILATOR ASSOCIATED PNEUMONIA,
2. THE PATHOGENESIS OF VENTILATOR ASSOCIATED PNEUMONIA ,
3. RECOMMENDED PREVENTIVE STRATEGIES AND THE SUPPORTING 
EVIDENCE,
4. RECENT UPDATES IN THE SURVIELLANCE OF VENTILATOR 
ASSOCIATED PNEUMONIA AND ITS PRACTICAL IMPLICATIONS,
5. THE ROLE OF SUBGLOTTIC SECRETION CLEARANCE IN 
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PREVENTION OF VENTILATOR ASSOCIATED PNEUMONIA,
6. LABOROTARY DIAGNOSTIC MODALITIES AND
7. CHALLENGES IN ANTIBIOTIC TREATMENT OF VENTILATOR-
ASSOCIATED PNEUMONIA.
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ETIOLOGY OF VENTILATOR ASSOCIATED PNEUMONIA
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In majority of the reports we came across the three leading etiologies for ventilator 
associated pneumonia are,(8,10)
 Gram negative bacilli, 
 Pseudomonas aeruginosa and 
 Staphylococcus aureus .
 But, it is important to  know that in early-onset ventilator associated pneumonia 
the causative organisms can be so called  community bacteriae such as 
 Streptococcus pneumoniae
 MSSA-methicillin sensitive S. aureus
 Haemophilus influenzae and  
 Gramnegative enteric bacilli,
On the other hand in late-onset VAP the causative organisms are,
 methicillin-resistant staphylococcus aureus (MRSA),
 Pseudomonas aeruginosa, 
 Acinetobacter baumannii and 
 Stenotrophomonas maltophilia.
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Majority of these organisms are possibly drug-resistant and are found to be 
associated with increased morbidity and mortality.
 We also note that an important unresolved issue in VAP is the definition of early 
and late onset VAP. Even though it remains unclear whether it concerns the number of 
hospital days or to the number of days after intubation, it is usually the first 5 -7 days 
which separate early onset and late onset VAP.(10)
 The etiological agents varies from patient to patient and may also differ with 
intensive care units, hospitals and countries and most importantly vary in a given ICU 
over the period of time. Thus, reported differences in VAP etiology can frequently be 
explained by 
 local specificities.
 The primary illness,
 Associated co-morbid conditions,
  Length of hospital stay and intubation,
 Previous exposure to antibiotics,
 Effectiveness or the lack of effective VAP preventive strategies and 
 The selection of the initial empiric antimicrobial treatment and susceptibility 
patterns of the pathogens.(8,10)
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 THE PATHOGENESIS 
OF 
VENTILATOR ASSOCIATED PNEUMONIA 
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 Figure showing the “Path to Ventilator-Associated Pneumonia”
As shown in pic above in the ventilated and critically ill patients, production of saliva decreases and the
subsequent environment promotes bacterial colonization in the mouth and oropharyngeal secretions, 
and can rapidly cause the development of pneumonia. 
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PATHOLOGY OF VENTILATOR ASSOCIATED PNEUMONIA.
FLOW CHART DEPICTING THE PATHOGENESIS OF VAP:
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THE INTERPLAY BETWEEN INVASIVE DEVICES AND RISK FACTORS.
The following three factors that are critical in pathogenesis of ventilator-associated 
pneumonia.
1. The colonization of the oropharynx with pathogenic microorganisms in intubated 
patients,
2. Micro-aspiration of these secretions filled with pathogens from oropharynx into lower
respiratory tract past (around) the endotracheal tube cuff.
3.Compromise of the host defense mechanism (in patients who are critically ill).(12) 
So, it is a the complex interplay between 
 The endotracheal tube and other invasive devices eg. naso gastric tube.
 The presence of risk factors (underlying disease, previous surgery and
antibiotic exposure, reintubation etc).
 The virulence of the invasive pathogen and 
 The patient's immunity .
which mostly determines the development of ventilator associated pneumonia . (8)
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ROLE OF ENDOTRACHEAL TUBE IN PATHOGENESIS OF VAP
By far the most obvious risk factor for VAP is the of endotracheal tube's presence 
of E. T.tube because of the following,
  It bypasses the normal mechanical factors preventing aspirations such as the 
cough reflex of glottis and larynx.
 It leads to is disruption of competent anatomical barriers allowing a 
straightforward communication between the supra-glottic space and the lower 
respiratory tract.
 The cuff of the endo-tracheal tube can only prevent gross aspiration not micro 
aspiration.
  If they become contaminated with bacteria from patients secretions even the  
contamination of ventilator circuit, heat moist exchangers and respiratory therapy 
equipment can lead to the development of ventilator-associated pneumonia.
 Trickling of pooled secretions around the ETT cuff.
 The perfect seal with the cuff is not possible due to, the formation of folds along 
the tracheal surface, frequent movement, inadequate inflation etc.
 The cuff also creates a mechanical obstacle to mucus clearance and impairs
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 muco-ciliary function.(13)
 The micro-aspiration can occur during intubation itself.
 Consequentially the endotracheal tube's presence and endo-tracheal suctioning 
can damage the tracheal mucosa facilitating tracheal colonization by pathogens.
BACTERIAL BIOFILM COATING ON ENDOTRACHEAL TUBE AND 
ITS IMPLICATIONS
Bacterial bio-film on the surface of endo-tracheal tubes has been observed 
universally  in mechanically ventilated patients. 
Evidence from recent data suggests a good relationship between microbial 
findings in the bio-film and bacterial colonization of the airway. The potential 
implication of bio-film in the pathological process of VAP is evident by the presence 
same microorganisms in the bio-film and the ones causing ventilator-associated 
pneumonia.(14)
Formation bio-film, as explained earlier by the pathogens on endotracheal tube's 
surface not only protects them from antibiotic and host defenses, these pathogens can 
dislodge during suctioning and the small fragments of glycocalyx can reach lower 
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respiratory tract carrying bacteria with them.
 INVASIVE VS NON-INVASIVE VENTILATION IN PATHOGENESIS VAP
The muco-ciliary clearance of secretions is impaired in intubated patients and the 
mucus flow is gravity dependent in the airways.
Also anatomic structures like stomach, sinuses, naso-pharynx and oropharynx can 
act as reservoir for pathogenic material and their normal flora can be replaced by more 
virulent strains and this pathogen rich material is continuously pushed forward by the 
positive pressure ventilation. 
Evidence also suggests that reintubation following extubation increases ventilator 
associated pneumonia rates and the use of non-invasive ventilation has been found  to 
significantly reduce ventilator-associated pneumonia rates.(8,12)
ASSOCIATION OF ENTRAL NUTRITION AND VENTILATIOR ASSOCIATED
PNEUMONIA
The “gastro-pulmonary hypothesis”  postulates that, as stomach becomes 
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colonized with gram-negative bacterium in critically  ill, it has a strong association with 
the development of ventilator associated pneumonia because,  they are the most 
common organisms isolated from sputum of patients with ventilator associated 
pneumonia. This theory suggests a retrograde migration and colonisation of oropharynx 
from the gastrointestinal tract which in turn gets colonized by pathogenic 
microorganisms endogenously (contaminated liquid injected into a naso-gastric tube), or
endogenously (duodeno-gastric reflux).And, subsequent sustained micro aspiration of 
this contaminated secretions from oropharynx or stomach,  pooled above around the 
endotracheal tube's cuff ultimately leads to infection of the lower respiratory tract (15).
There is evidence suggesting that a gastric pH of 3.5 plays a role in prevention of 
bacterial colonization which maintained in fasting conditions and a pH 4.0 is associated 
with significant bacterial colonization of stomach and its content in clinically significant 
proportions, resulting in increased incidence of nosocomial pneumonia.
But in Critically-ill patients  especially who are ventilated and coagulopathic, 
stress-related gastro-intestinal bleeding results in higher mortality, compared to patients  
without evidence of bleeding so, warranting stress ulcer prophylaxis.(15), which 
increases gastric pH.
Enteral feeding especially continuous feeding through naso gastric tube increases 
gastric pH and may,tends to increase gastric residual volumes. Gastric residual volume is
one of the risk factors for tracheo-bronchial aspiration by patients on ventilators but, 
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results of a recent systematic review is inconclusive.(16).
  But, early enteral nutrition has got its advantages, as it reduces the hospital 
mortality. If initiated within 48 hours of mechanical ventilation, enteral nutrition in 
critically ill has  shown to reduce mortality. This is especially beneficial in the sickest 
patients ( hemodynamically unstable, with multiple vasopressors support) and there was 
no evidence of harm due to initiation of early enteral nutrition.(17)
ALTERED IMMUNOLOGY IN CRITICALLY ILL AND ITS ASSOCIATION WITH
VAP
In patients who are critically ill pathogenic microorganism replaces the normal 
oropharyngeal flora due to cross infection from other patients and medical personnel, 
contaminated equipments (airway devices, ventilator circuits etc.)
Recent research in immunology shows in critically ill patients with septicemia and
trauma, even prior to  the emergence of nosocomial infection they can have ineffective 
phagocytosis and may act as functionally immune-suppressed. Due to their apoptotic 
loss of host cells adaptive immune system several days after admission in to ICU they 
are at a greater risk of developing ventilator associated pneumonia.(8,12,18,19)
This effect is attributed to the ineffective or impaired neutrophil phagocytic 
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activity due to detrimental actions of the anaphylatoxin C5a. Acquisition of nosocomial 
infections is attributed to a combined of T-cells monocytes and neutrophils dysfunction 
in recent research.
Researchers also suggested that infections in critically ill in contrast to healthy 
controls can be predicted by elevation of v regulatory T-cells, CD88 expression- 
neutrophil dysfunction and monocyte HLA-DR expression-
monocytedeactivation(8,18,19)
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PREVENTION OF VENTILATOR ASSOCIATED
PNEUMONIA
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RECOMMENDED VAP PREVENTION STRATEGIES AND THE
SUPPORTING EVIDENCE
Current recommendations for adult intensive care unit patients for prevention of 
ventilator-associated pneumonia - ventilator associated pneumonia bundle 
interventions are as follows (2),
 Head end elevation of the cot by 30-40 degrees,
 Strict cuff pressure maintenance in the E.T. tube (20-25) cm H20
 Oral hygiene
 Circuit changes at regular intervals or when soiled with secretion ,
 Using heated humidifiers and HMEs (heat and moisture exchanger) ,
 Providing oral care with chlorhexidine and water-soluble mouth moisturizer ,
Use of specially designed E.T. tube for removing secretions, 
Use of Closed- in-line suction to remove tracheal secretions,
 Assessment for kinetic bed therapy
 Employing sedation holiday
 Appraisal of weaning readiness with spontaneous breathing trials 
 whenever feasible
 Stress related gastric ulcer prophylaxis and
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 DVT prevention strategies. 
    The evidence behind these preventive strategies are discussed in detail in coming 
sections.
A) Nursing and Respiratory Care 
Head-end Elevation of the Bed
In the absence of contraindications, all ventilated patients should be nursed with 
head end of the bed elevated at an angle of 30-40 degrees. Incidence of ventilator 
associated pneumonia due to aspiration was found to be higher in patients who were
not nursed in the head up position. Head end elevation of the bed for any degree less
than 30 was not found to be beneficial in reducing risk of aspiration. Patients 
receiving entral  tube feeds were found to be at higher risk for aspiration leading to 
ventilator associated pneumonia.
Maintaining Endotracheal tube's Cuff Pressure
Maintenance of endotracheal tube's cuff pressure between 20-25 cm H2O.
Ventilator associated pneumonia incidence was found to be reduced in patients 
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whom cuff pressure was maintained above 20 cm H2o.
During mechanical ventilation endotracheal tube cuff pressure decreases 
spontaneously and can result in aspiration of pooled oropharyngeal secretions into 
the lower respiratory tract thereby increasing the risk of ventilator-associated 
pneumonia.
The Centers for Disease Control and Prevention does not recommend maintenance 
of endotracheal cuff pressures above 20 cm of h2o.
Circuit Change
The centers for disease control and prevention recommends changing of ventilator 
circuit only when visibly soiled, as frequent replacement of ventilator circuits did 
not reduce the incidence of ventilator associated pneumonia.
Heated Humidifiers, and Heat and Moisture Exchangers
Due to lack of evidence supporting the use of heat and moisture exchangers and 
heated humidifiers, The Centers for Disease Control and Prevention does not 
recommend their use as. studies failed to demonstrate a significant reduction in the 
incidence of ventilator associated pneumonia when either heated humidifiers or heat
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and moisture exchangers were used.
 The Centers for Disease Control and Prevention recommends that heat and 
moisture exchangers should be changed every 48 hours or on visible soiling  and/or 
on evidence of mechanical malfunction.
Some authors have also proven an absence of adverse effects, with regard to either 
technical or clinical ventilator performance, even if the heat and moisture 
exchangers were not changed up to 120 hours. 
Also, there is no evidence supporting that the frequent changes in heat and moist 
exchangers reduces the incidence of ventilator-associated pneumonia or endo-
tracheal tube occlusion (2). 
 Oral Care 
Oral decontamination with 2% chlorhexidine solution was evaluated in an earlier 
randomized controlled trial and a meta-analysis for the prevention of ventilator-
associated pneumonia in comparison with normal saline solution.
Although using chlorhexidine mouth wash statistically reduced the incidence of 
ventilator-associated pneumonia per 1,000 ventilator days there no was difference in 
the incidence of gram negative oropharyngeal colonization and overall mortality.
52
 Patients in the chlorhexidine group also reported a higher incidence of oral mucosal 
irritation which restricted the number of times oral care was administered.
Secretion Removal with Specially Designed Endotracheal Tubes
  Several authors reported reduced rates of early onset ventilator associated 
pneumonia when specially designed endotracheal tubes capable of continuous 
aspiration of subglottic secretions were used.  Hence the American Thoracic Society 
document recommends the use of specially designed endotracheal tubes capable of 
providing continuous suctioning of subglottic suction (3). The use of continuous 
subglottic secretions was found to cause mucosal injury by some observers.
Routine change of standard endotracheal tube to an endotracheal tube with a 
subglottic suction lumen is not recommended due to the risk of the aspiration during 
the change.
The Centers for Disease Control and Prevention recommends,
Use of specially designed endotracheal tube with a dorsal lumen proximal to the 
endotracheal cuff for the removal of pooled secretionby suctioning.  
Ensure clearance of secretions proximal to the endotracheal tube cuff prior to 
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deflating the ETT cuff or changing the tube for any reason.
Patients expected to require more than 72 hours of mechanical ventilation, the use 
of  endotracheal tube with special port for removal of subglottic secretions removal 
port, was found to reduce ventilator-associated pneumonia and duration of 
mechanical ventilation.
The working group of the centeres for disease control and prevention recommends 
use of these special endo-tracheal tubes in the case of a hospital wide practice and to
appropriately determine its use patients who are expected to require prolonged 
mechanical ventilation. As patients requiring emergency intubation fall into this 
category often, these special tubes should be available in the casualty or ED and 
other areas where emergency intubations for are performed
Closed, In-Line Suctioning
The working group of The  Centers for Disease Control and Prevention does not 
recommend the use closed in-line suctioning, in the protocol for prevention of 
ventilator associated pneumonia. 
      An earlier study observed, the use of in-line suctioning within 3 days, Significantly 
enhanced microbial growth within the lower respiratory tract, Normal saline instilled
with endotracheal suctioning lead to dispersion of microorganisms into the lower 
respiratory tract. But, exposure of hospital personnel to infected respiratory 
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secretions was significantly decreased with closed systems. 
So, The Centers for Disease Control and Prevention does not make any preferential 
recommendation for the use of either single-use open suction system or multi-use 
closed suction system. This is because, researchers could not demonstrate a decrease 
in the incidence of ventilator-associated pneumonia s with either systems.
A meta-analysis of 15 randomized trials comparing closed suction system to open 
suction system, failed to demonstrate any significant difference in incidence of 
ventilator-associated pneumonia and mortality between both the groups.
Kinetic Bed Therapy
The use of Kinetic bed therapy (continuous lateral rotation) reduced the incidence of 
VAP, in  a prospective, randomized, multicenter study in 2004 (4) . 
However, as kinetic bed therapy significantly decreased incidence of ventilator-
associated pneumonia and lobar atelectasis, it did not offer any benefit with regard to
duration of mechanical ventilation or mortality.
Hence there is no strong recommendation for the routine of kinetic bed therapy, as it 
requires a special bed that may not be available at all intensive care units.
Sedation Reduction
Use of regular spontaneous breathing trials, i.e. testing patient's ability to sustain 
55
adequate ventilation, oxygenation and breathing comfort without ventilatory support,
has been shown to significantly reduce duration of mechanical ventilation for acute 
respiratory failure.
 Daily cessation of continuous infusions of sedative medications, after the second 
day of intubation was found to decreases the duration of mechanical ventilation and 
the need for diagnostic testing to evaluate impaired mental status that occurs after 
intensive care admission.
Use of sedation algorithms to frequently adjust sedative and analgesics doses and 
maintaining wakefulness was also shown to reduce number of ventilator days [C]. 
 individualisation and modification of recommendations, to each intensive care unit 
is recommended. 
• Essential sedation reduction elements include,
• Use of sedation scales for regular patient assessment,
• Cessation of sedation daily or hourly dose reduction in patients who are over-
sedated, 
• Opiates should be used as an adjunct for pain and 
• Use of bolus dose to achieve desired level of sedation to be considered prior 
increasing the infusion rates. 
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The contraindications to sedative cessation include,
• Neuromuscular paralysis, 
• Intense respiratory failure 
• Withdrawal of life support .
Weaning Readiness
Use of Brief weaning trials daily (or more frequently), allowing early assessment of 
patients' ability to sustain breathing comfort, ventilation, oxygenation and 
hemodynamic stability are recommended. 
Use of brief weaning trials was found to reduce number of days of mechanical 
ventilation significantly.
 The patient's tolerance and physiological response to 30-60 minutes of 
unsupported (e.g., continuous positive airway pressure  or T-piece) or minimally 
supported breathing (e.g., with pressure support of 7 cm H2O) can be done by 
respiratory therapist or nurse-driven protocols, and can be communicated to 
physicians.
 Weaning trial results should be incorporated only after the patient's level of 
consciousness, airway stability, illness course and hemodynamic status, are 
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considered.
 The weaning trial can be temporarily postponed in the presence of:
• Raised Increased intracranial tension, 
• Severe respiratory failure such as FiO2 requirement greater than 50%, 
• PEEP or positive end-expiratory pressure greater than or equal to eight,, 
• Whenever prone position is used, 
• In case of  airway related problems or hemo-dynamic instability , 
• Whenever neuromuscular blockade is used,   
• Apnea and
• Expected life support removal.. 
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B) Medications 
Stress Ulcer Prophylaxis
The Centers for Disease Control and Prevention does not make any 
recommendation for the preferential use of sucralfate, H2-antagonists, and/or 
antacids for stress-bleeding prophylaxis in patients receiving mechanical 
ventilation. 
In a randomized clinical controlled study on 52 patients in an intensive care unit 
comparing ranitidine vs sucralfate for stress ulcer prophylaxis demonstrated that
there was no difference in the incidence of gastrointestinal bleeding between the 
ranitidine and sucralfate groups, but was higher in the control group. 
In the ranitidine group the mean gastric pH was higher significantly . 
In the ranitidine group the frequency of positive cultures with gram-negative 
bacteriae was found to be higher than the sucralfate group (75% compared to 33% 
with sucralfate). 
In all three groups( i.e. ranitidine, sucralfate and control groups) the frequency of 
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positive growth in the broncho alveolar lavage culture was similar (5) .
Considering the available evidence discontinuation of stress ulcer prophylaxis for 
the patient should be considered ,
• Once they are extubated, 
• When patient is transferred out of the intensive care unit and there is no 
significant gastrointestinal bleeding,
• In the absence of spinal cord and brain trauma,
•  Patients getting enteral nutrition,
• Patient not on a high-dose steroids therapy and/ is not on any outpatient 
medication.
Venous Thromboembolism Prevention:
For most patients in the intensive care unit or those with risk factors for 
development of venous thromboembolism, venous thromboembolism prophylaxis is 
recommended. 
Recent study, reviewing thromboembolism prevention for a variety of clinical 
conditions found out, most patients in the hospital have one or many risk factors for 
developing venous thromboembolism. Thromboprophylaxis should be used based on
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solid principles and scientific evidence, as cumulative risk factors are present in 
most patients. 
A strong correlation exists between asymptomatic deep venous thrombosis and later 
development of venous thromboembolism. 
The prophylaxis for symptomatic deep venous thrombosis and pulmonary em-bolus 
should be a top priority as these complications are associated with increased 
mortality, increased costs and long-term complications. 
Pneumatic compression devices increase venous outflow and/or reduce stasis within 
the leg veins therefore, should be considered for all patients who are at high risk for 
bleeding.
 Even though these devices have been shown to decrease the risk of DVT but not to 
reduce mortality or pulmonary embolism. 
 These devices are acceptable for use in patients at increased risk for bleeding or can
be used in addition with anticoagulant therapy. 
It is recommended that all patients should be assessed for their risk of venous 
thromboembolism on admission to a critical care unit and accordingly, should 
receive thromboprophylaxis. 
Although critically-ill patients are at a high risk for developing deep vein thrombosis
and pulmonary embolism, are also at the risk for bleeding, thrombocytopenia 
coagulopathy and renal impairment. 
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So, different therapies for thromboprophylaxis might be appropriate, including 
combination of an anticoagulant medication (heparin s or fondaparinux) and 
intermittent compression devices at different times. 
The so called the VAP bundle interventions discussed above and the preventive 
practices for all hospital acquired infections are strictly followed in our ICU. Also 
awareness among the healthcare personnel in our hospital in general and our ICU in 
particular is created through continuous education pro-grammes.
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 RECENT UPDATES IN THE SURVIELLANCE OF
VENTILATOR ASSOCIATED PNEUMONIA AND ITS
PRACTICAL IMPLICATIONS
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The very definition and the diagnostic criteria for ventilator-associated pneumonia
or VAP kept on evolving and changing since the time its been first recognised and 
continue to change every passing year. 
For example,
The CDC Centers for Disease Control and Prevention  defined ventilator-
associated pneumonia (VAP) in 2002, as 
“A new or progressive and persistent radio graphic abnormality developing in a 
patient on mechanical ventilation or within 2 days of mechanical ventilation, who must 
also demonstrate: one or more systemic signs (pyrexia, leucopenia or leucocytosis, or 
altered mental status in those >70 years of age) and selected pulmonary criteria (eg, 
change in respiratory secretions, new onset of cough, dyspnea, crepitations, bronchial 
breath sounds, or worsening oxygenation).
 And with some additional criteria for VAP in immuno-compromised patients was 
also released then.
This above definition of ventilator-associated pneumonia could not be specifically
used for surveillance purpose as it had been found to be neither sensitive nor specific.  
The chest radiograph which was integral part of that definition, always had its 
pitfalls, when it comes to diagnosing ventilator-associated pneumonia because, haziness 
in a chest radiograph especially in a portable film could be due to various conditions like
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pneumonia, atelectasis,  pleural effusion or pulmonary edema and therefore making it 
unreliable in the diagnosis of ventilator-associated pneumonia alone.
 The most accurate radio-graphic signs for ventilator-associated pneumonia were 
air broncho-gram and volume loss (not haziness) in suspected patients, which had a 
diagnostic accuracy of 64% and was proven in an earlier autopsy study (20). But, this 
investigation is subject to observer variability.
The given clinical features are every bit fallible for VAP surveillance purpose also 
proven in an earlier study as the sensitivity and specificity was around 69%-75% only  
(i.e.  a radio-graphic opacity and 2 of 3 signs of infection  such as pyrexia, leucocytosis, 
and mucopurulent sputum)(21)
Also, it was difficult to differentiate between colonization and infection with 
microbiological evidence as in various studies, about 22% of 95 intensive care unit 
patients became colonized, within 24 hours of intubation (22–24). Moreover, another 
issue is that, not all the laboratories report quantitative culture.
 To makethe surveillance of VAP more objective, as the earlier definition of VAP 
was less objective with parameters like chest x-ray which is very subjective, the CDC – 
Centers for Diagnostic Control established a task force in 2011to develop new a 
surveillance strategy that can be put into practice by the NHSN or National Healthcare 
Safety Network of USA and therefore a new set of surveillance recommendations are 
released in January 2014. This recommendation is based on non subjective, efficient, 
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and possibly automatable criteria that will deliberately denote a wide range of conditions
and complications which occur in ventilated patients in adult critical care units. 
Thus a new collection of conditions, ventilator-associated events or VAE was 
coined, collection all the states that consequence a significant and continuous 
impairment in oxygenation in mechanically ventilated adult patients. It is now defined in
patients ventilated for more than 2 days, as a more than 20% addition in the daily 
minimum fraction of inspired oxygen or an addition of at least3 cm H2O in the daily 
minimum PEEP to hold up oxygenation.
 VAE definition may be fulfilled by both infectious conditions and noninfectious 
conditions. The definition VAE is three tiered, as follows:
Tier 1: ventilator-associated condition (VAC) after a 2 day period improving 
oxygenation or status quo the patient develops hypoxemia for a sustained period of more
than 48 hours 0r 2 days irrespective of cause of hypoxemia.
Tier 2: infection-related ventilator-associated complication (IVAC) —in addition to 
VAC -hypoxemia develops along with picture of generalized infection or inflammation, 
and antibiotics are given for at-least four days.
Tier 3: probable or possible ventilator-associated pneumonia (VAP) —In patients 
with IVAC extra lab-evidence of abnormal WBC count, presence of neutrophils in 
respiratory secretion specimen of bankable quality, or (=possible VAP)/and (=probable 
VAP), presence of respiratory microorganisms on quantitative cultures,
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 Additional criteria are also given for use in meeting the possible VAP or probable VAP
 definitions.(25)
 The Centers for Disease Control with the initial users feedback has made many 
modifications of the definitions in VAE surveillance algorithm which was utilised by the
NHSN such as,
 In some mechanically ventilated patients,   PEEP is not used initially due to 
associated conditions for example, hypo-tension or, raised intracranial pressure and 
during spontaneous breathing trials, sometimes PEEP is reduced for short duration. But 
PEEP may be put back or increased when these conditions revert and the subsequent 
increase in PEEP will represent VAC in accordant to the new definition. So, these 
situations should be taken into account before recording the event.
E.g. if a patient is receives gentamycin for preexisting urinary tract infection, it 
shouldn't  confused with  respiratory tract infection treatment , this issue is addressed by 
limiting the qualifying list of antibiotics used in treatment of ventilator associated 
infection than those used for other infective conditions.
To make sputum examination reporting less rigorous laboratories – some labs may
report counts of neutrophils  and/or squamous epithelial cells  in respiratory secretion 
specimen using various quantification outsets than recommended in the new algorithm.
Interventions like increasing the Fio2 or increasing PEEP level for comfort care in
case of terminally ill shall not be defined as  a VAC. 
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Above mentioned and many such doubts, clarification and problems in special 
situations are answered by NSHN in a new release and it is available in their website.
“http://www.cdc.gov/nhsn/pdfs/pscManual/10-VAE_FINAL.pdf “
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The aim of this new  VAE definitions is to encourage survey in a single and concordant 
manner at all the adult hospitals as it changes the importance in mechanically ventilated 
adult patients from lung infection alone to a dependable, various set of conditions with a 
common thread – deterioration in respiratory function in mechanically ventilated. 
We decided to start the surveillance with this new CDC algorithm for our study so
that, we get an opportunity to learn more about its practical implications in VAP 
surveillance in our ICU.
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THE ROLE OF SUBGLOTTIC SECRETION CLEARANCE
IN PREVENTION OF VENTILATOR ASSOCIATED
PNEUMONIA
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VAP has become a common hindrance in intensive care unit and it is associated 
with prolonged ICU stay and hospital stay, increased mortality, the causative pathogens 
are multidrug-resistant and results in a huge increase in healthcare spending.
Focused VAP prevention measures that could reduce VAP incidence in critical care 
setting could positively affect patient safety in critical care units so, we should prioritize 
them.
As given in VAP bundle and other preventive recommendations, currently multiple 
interventions are in use to prevent VAP.
 But, interferences affiliated to the endotracheal tube (ETT) itself, are attracting more 
interest, As one of the main risk factor for VAP development in ventilated patients is the 
endotracheal tube.
A standard endo-tracheal tube is reasoned to be a leading risk factor for VAP because,
 It acts as a storage tank for potentially infecting microorganisms,
 It acts a conduit between the oropharynx and the lower respiratory tract by 
bypassing inherent defenses, 
 It modifies the ability to clear secretions as the patient cannot cough,
 By keeping the epi-glottis open, it allows oral-supraglottic secretions into the 
lower respiratory tract,  and
 It does not prevent micro-aspiration of secretions and the eventual bio-film 
formation.
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A standard  or a conventional endo-tracheal tube ETT C:
Figure showing- oropharyngeal secretion pooling above the cuff of the ETT C:
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The subglottic secretion drainage or SSD is engineered to remove secretions 
accumulating above the ETT's cuff which is removed either by intermittent or 
continuous suctioning of in the subglottic area.
This intervention may cut down the risk of aspiration and prevent VAP.
Figure showing ETT SS-Subglottic Secretion Drainage:
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 separate lumen for 
removal of subglottic 
secretions
 port for aspiration of 
subglottic secretions
These specially designed endo-tracheal tubes for subglottic secretion drainage possess 
an isolated dorsally placed lumen  which opens above its cuff, through the port 
secretions can be aspirated by negative pressure as shown in the figure below. 
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Till date many studies had been done regarding subglottic secretion removal - in 
reducing incidence of ventilator associated pneumonia. Some of these studies showed 
decrease in the incidence of VAP (26–30)
While some other studies suggested when subglottic suction drainage is 
employed, a prolongation in the duration of time to the development of ventilator 
associated pneumonia is noted (26,31,32).
The benefit of subglottic secretion drainage in VAP prevention has been evidenced in 2 
meta-analyses. 
a) A study showing (33) showing a reduction of 50% in the risk of acquiring
ventilator associated pneumonia-in this analysis 2,442 patients were evaluated from 
thirteen RCTs, but there was no reduction in mortality. 
b) One more study  (34) reported similar ventilator-acquired pneumonia reduction - 
were reported in a small meta analysis - mainly through reduction of ventilator 
associated pneumonia rates in the first 5 to 7 days after intubation.
Subglottic suction drainage seems to have its proven advantages and is currently 
recommend in the VAP bundle and it is reasonably cost-effective. It is not routinely used
in high risk patients in whom the anticipated duration of ventilation is more than 48 hrs 
because lack of concrete evidence in its advantage, lack of availability and lack of 
consensus among healthcare providers of various specialties.
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So, further research is required to learn more about the efficacy of using endo-
tracheal with subglottic suction drainage in reducing the incidence of ventilator 
associated pneumonia.  (35)
 
80
LABOROTARY DIAGNOSTIC MODALITIES
FOR VAP
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The current VAP surveillance algorithm recommends three laboratory 
investigations with the notable omission of the chest x ray.
Chest x ray findings have been taken away in the recent CDC criteria because of its 
subjectivity without much increase in accuracy, In intensive care, chest radiography 
may sill play a clinical role, as the new CDC released VAP algorithm is intended for 
surveillance purposes only.
The recommended laboratory investigations are ,
WBC or white cell counts 
• Leukocytosis 
WBC count above 12,000 /cu.mm (0r) 
• Leukopenia 
-WBC count below 4,000/cu.mm.
Presence of purulent respiratory secretions 
  Secretion-sample obtained from the lungs, bronchus/bronchi and trachea when seen 
under low power field should contain more than 25 neutrophils and less than 10 
squamous epithelial cells.
So, it is not merely the change in color and consistency of the respiratory secretions.
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Quantitative microbial culture  of
• Endo-tracheal secretion /aspirate, 
• Pleural fluid specimen and 
• Lung tissue sample.
Respiratory samples for microbial culture can be obtained using one or more of the 
following techniques(1)
1. ETA or Endotracheal aspirate is easiest to obtain where the specimen is sucked into a 
sterile container connected in line with the suction apparatus.
2. Broncho alveolar lavage (BAL): This technique requires bronchoscopic guidance for 
obtaining the sample.
3. Mini-broncho alveolar lavage (mini-BAL):Blindly performed since bronchoscopic 
guidance is not used.
4. Protected specimen brush (PSB): In this technique catheter with a brush at the tip is 
used to rub it against the bronchial wall.
5.Pleural fluid sample is obtained by a sterile aspiration technique and not from 
indwelling chest tubes or drains.
6.Lung biopsy even-though very rarely used for diagnosis of pneumonia is obtained by 
broncho-spic guidance or CT guided fine needle biopsy.
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Threshold values recommended for probable ventilator associated pneumonia in 
quantitative culture reports are (6),
Technique used in sample collection                                       Values needed for diagnosis
Lung Tissue Sample:                                                                       10,000 cfu/gram of 
                      tissue
Bronchos-copy Specimens:
B BAL- Broncho Alveolar Lavage     10,000 cfu/ml
B PBAL- Protected Broncho Alveolar Lavage     10,000 cfu/ml
B PSB- Protected Specimen Brushing                                                1,000  cfu/ml
Non Bronchos-copy (Blind) Specimens:
Technique used in sample collection                                       Values needed for diagnosis
NB BAL-Broncho Alveolar Lavage     10,000 cfu/ml
BB PBAL- Protected Broncho Alveolar Lavage     10,000 cfu/ml
ETA – Endo-Tracheal Aspirate                                                          100,000cfu/ml
cfu=colony forming units seen in the microbiology culture.  
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≥ANTIMICROBIAL TREATMENT OF VENTILATOR-
ASSOCIATED
PNEUMONIA.
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Although our research is limited to the surveillance of VAP, it is worthwhile to 
discuss the treatment and the difficulties associated with the antibiotic therapy  (1)  
The antibiotic therapy for VAP depends on few factors,
     The duration of mechanical ventilation,
      The local microbial pattern of the particular ICU and the hospital.
      The sensitivity and resistant patterns of the above mentioned organisms and 
     More importantly in India the affordability of the patient for costlier broad spectrum 
antibiotic therapy.
      The conventional understanding is to treat early-onset VAP with narrow spectrum 
antibiotics and late-onset VAP with broad spectrum antibiotics like carbepenams, 
vancomycin, teicoplanin, collistin etc.
      But this practice is often not practical especially in referral centers and tertiary 
hospitals as a good number the patients receive antibiotics even before ICU 
admission.(1,7)
      Also the fact that organisms like pseudomonas , acenetobacter, ESBL(extended-
spectrum-beta-lactamases) producing gram-negative bacilli etc are inherently 
resistant to high end antibiotics or sometimes can develop resistance towards a 
particular antibiotic during therapy.
      Apart from the cost factor the prolonged antibiotic therapy required to treat ventilator
associated pneumonia can have its adverse effects like clostridium difficle colitis 
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fungal infection, renal toxicity, thrombocytopenia etc.
       Although appropriate, individualized antibiotic therapy based on spectrum of 
coverage is needed for VAP, unnecessary broad-spectrum antibiotic usage should be 
avoided.
      So, early de-escalation is strongly recommended as soon as the microbiology results 
are available or on clinical improvement, not only to recover costs but also to avoid 
development of resistance (7) .
      Therefore, emphasis on continued research and sustained efforts on VAP prevention 
strategies cannot be over-emphasized in view the above discussed issues in antibiotic
treatment of VAP. 
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MATERIALS AND METHODS
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Detailed research plan: 
STUDY DESIGN:
A Prospective Observational Study comparing the effect of endotracheal Tube with 
Subglottic Suction Port ETT SS vs standard Endotracheal tube ETT C on Incidence 
of Ventilator associated Pneumonia in patients ventilated for > 48 hrs in ICU. 
SETTING: 
 Christian Medical College and Hospital, Vellore, Tami Nadu, India is a 2500 bedded
hospital, with more than 100 beds in various intensive care units. It is a tertiary care 
center which caters to patients from all over India, South Asia, Middle East And 
some African countries.
This study is exclusively done on patients admitted to 13 bed Surgical ICU (SICU) 
& 6 bed AICU in Christian Medical College, Vellore. Recruited patients data will be 
collected and followed up till discharge from hospital. 
Methods:
Adult patients admitted to intensive care unit (ICU) with duration of artificial 
respiration >48 hrs will be included in this study.
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 The type of ET tube (ETT C or ETT SS) used for intubation will be noted along 
with other variables like Patient details, diagnosis, per-existing illness, APACHE II 
score (score based on severity of illness and any other long standing illness), number
of days on ventilator, number of days ICU stay & hospital stay. 
Standard VAP bundle interventions to prevent ventilator associated pneumonia is 
given to all intubated patients in the ICU as a standard practice irrespective of type 
of endotracheal tube used for intubation ETT C or ETT SS.
 Prior to our study, uniform objective surveillance algorithm for ventilator associated 
pneumonia did not exist in our ICU and Hospital. 
Patients with fever, increased respiratory secretions, increased or decreased White 
cell count associated with sustained decrease in oxygenation will be screened for 
microorganisms from endo tracheal secretions. 
Surveillance for Ventilator Associated Pneumonia in this study will be in accordance
with the latest “Surveillance for ventilator-associated events in the National 
Healthcare Safety Network (NHSN)” guidelines released in Jan 2014. 
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Participants: 
Inclusion criteria: 
Adult Patients between 16 and 80 years of age who receive mechanical ventilation 
for > 48 hrs in ICU. 
Exclusion criteria: 
Patients intubated outside our hospital. 
Patients suspected to have aspirated or at risk of aspiration prior to or during intubation. 
Admitted with a diagnosis of community acquired pneumonia. 
Pregnant women & Children. 
Patients recruited to other studies. 
Refusal of assent. 
Primary outcome: 
Incidence of VAP or Ventilator Associated Pneumonia and 
Secondary outcomes: 
All VAEs - Ventilator Associated Events 
VAC-Ventilator Associated Condition , 
IVAC- Infection related Ventilator Associated Condition , 
Possible VAP- Ventilator Associated Pneumonia and 
Probable VAP- Ventilator Associated Pneumonia 
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 and
Duration of mechanical ventilation, 
Length of ICU stay, 
Length of hospital stay and
In hospital mortality. 
Sample size: 
To test whether any significance difference in the incidence of VAP among the two 
groups, the minimum required samples to be studied is 80 in each group. So the total
sample size was determined as 160. 
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The formula used for the sample size calculation was 
Here p1 = 0.30, p2=.516, type 1 error =5% and power=80%. 
(Reference: Zheng et al 2008 (8)) 
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Statistical methods: 
       The overall incidence of VAE and VAP per 1000 ventilator days was calculated using
the formula given by CDCs NSHN in the new VAP surveillance algorithm. 
        VAE =no of events/ no of ventilator days x 1000 ventilator days
The incidence of VAP in two groups was compared using two sample proportion 
test. 
The association between the clinical variables and the incidence of VAP was 
analyzed using Chi-square test. 
      Logistic regression analysis was used to calculate the relative risk and 95% CI of 
VAP incidence.
Descriptive statistics and frequencies was used to represent all the variables along 
with appropriate diagrams. 
      SPSS 17.0 software is used for data analysis. 
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Detailed diagrammatic algorithm of the study design:
Adult patients receiving mechanical ventilation for more than 48 hrs in ICU
Group I                                                                              Group II
Patients with ETT C                                                   Patients with ETT SS   
Continue VAP bundle without                                          Continue VAP bundle with
SSD-subglottic secretions                    SSD-subglottic secretions  
drainage                                                                             drainage
Surveillance for                                                                   Surviellance for
VAP & VAE                                                                         VAP & VAE
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The following CDC algorithm is  used to find out the incidence of VAP and VAEs in our 
ICU for this study:
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RESULTS
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Between April 2014 to September 2014 one hundred patients  required mechanical
ventilation (  43 in ETT SS group and 57 in ETT C group ) for more than 48 hours were 
recruited into our study.12 patients were later excluded from the study (all ETT C)as 
they were re-intubated with ETT SS after 24 hours due to various reasons like 
• Tube Block,
• Failed extubation,
• Accidental extubation,
• Cuff damage, 
• Tracheotomy etc.
Data of 88 patients  were analysed of which, 43 of them in  ETT SS group and 45 
others in  ETT C group.
DEMOGRAPHIC VARIABLES AMONG STUDY PARTICIPANTS:
GENDER:
Among the patients recruited in the ETT SS group there were 10 females and 33 
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males and in ETT C there were 14 females and 31 males, with the 'p' value = 0.0408. 
There was significant gender difference within the two groups, depicted in the following
table.1
TABLE.1: GENDER
E.T.TUBE TYPE ETT SS ETT C TOTAL
MALE 
10  (23.3%) 14  (27.3%) 24  (27.3 %)
FEMALE
33  (76.8%) 31  (68.9%) 64  (72.8%)
TOTAL
43  (100%) 45  (100%) 88   (100 %)
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AGE:
 The mean age of patients in ETT SS group was 41.4 ± 14.72 years compared to 
ETT C group 48.02 ± 15.92 years.
 ETT SS group patients were significantly older than ETT C group.
Depicted in table.2.
TABLE.2: AGE
ETT TYPE ETT C ETT SS p-value
AGE in years  41.4 ± 14.72 48.02 ± 15.92 0.0458
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Figure showing mean age distribution between two patient groups ETT C and ETT
SS
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PREVALENCE OF ETA-MICROORGANISMS IN THE STUDY POPULATION:
A quantitative culture of more than 1,00,000 colony-forming units from a 
endotracheal aspirate is considered significant. In the study group, the distribution of 
patients with significant quantitative cultures is shown in the table below. All respiratory
secretion specimens were ETA- endo tracheal aspirates collected by protected 
telescoping catheter sampling. The number of positive cultures and the organisms grown
are given the following table.3.
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TABLE.3:PREVALENCE OF MICROORGANISMS :
ETT 
TYPE
           ETT SS Number of
Positive 
cultures
             ETT C Number of
Positive 
cultures
Micro-
organisms
                            
Acenetobacter Baumanii 
NFGNB or Non 
Fermenting 
Gramnegative Bacilli       
Pseudomonas species        
Klebsiella                           
E.coli                                  
 5 
4 
2
1
0
                             
Acenetobacter Baumanii 
NFGNB or Non 
Fermenting 
Gramnegative Bacilli       
Pseudomonas species        
Klebsiella                           
E.coli                                  
5
1
0
1
2
TOTAL 12              
                  
                                            
9
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CLINICAL STATUS OF PARTICIPANTS
There were few significant differences in the baseline characteristics between ETT C 
and ETT SS patients.
As for as the associated co-morbid illnesses were concerned there were 
differences between the two groups showing statistical significance . 
The ETT C group had lesser number of patients with  HTN -Hyper tension 5 0ut 
of 45 (11 %) compared to ETT SS group 13 out of 43 (30.23 %) 'p' value  = 0.026 which
was statistically significant, shown in the following table.4.
TABLE.4:
ETT TYPE ETT SS ETT C p-value
HYPERTENSION 13 (30.23%) 5 (11.11%) 0.026
The ETT C group had lesser number of patients with DM-  diabetes mellitus  8 out of  
45 (17.78%) compared to ETT SS group 15 out of 43 (34.88 %) 'p' value  = 0.067 which
turned out to be not statistically significant as shown in table.5:
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TABLE.5:
ETT TYPE ETT SS ETT C P-value
 DM 15 (34.88%) 8 (17.78%) 0.067 
Among other co-morbid conditions there were significant differences between the two 
groups in the number of patients with Tuberculosis-TB,Chronic Liver Disease-CLD and 
Thyroid disease as they were significantly higher in ETT SS group compared to ETT C 
group.
Co-morbid illnesses in the two groups are shown in the table.6:
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TABLE.6: COMORBID ILLNESS:
 
TYPE OF ETT ETT SS ETT C p-values
IHD 5 (11.6%) 4 (8.9%) 0.67
CLD 2 (4.65%) 0 0.143
CKD 3 (6.98%) 4 (8.89%) 0.74
COPD 1 (2.23%) 2 (4.44%) 0.582
TB 4 (9.3%) 0 0.037
THYROID 
DISEASE
0 2 (2.44%) 0.162
ATRIAL 
FIBRILATION
3 (6.98%) 0 0.071
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The APACHE II SCORE-"Acute Physiology and Chronic Health Evaluation II” Score 
was used to measure the severity of disease in patients admitted to our ICU. The mean 
Apache II score did not show any statistical significance between the two groups even 
though it was higher in ETT SS group, as given in the table.7: below.
TABLE.7:
ETT TYPE ETT C ETT SS p-value
APACHE II score 21.84   ±  8.49 26.14  ±  10.97 0.0520
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PRIMARY OUTCOME
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PRIMARY OUTCOME:
INCIDENCE OF VAP:
In spite of a positive microbial growth on 21 occasions in recruited patients (both 
the groups together), with  cfu  > 100,000 in ETA, after 48 hours of ventilation as shown
in table.3 earlier, when on applying CDC VAP Surveillance algorithm only 2 out of 88 
patients had probable VAP, and only 8 patients in total had VAE- Ventilator Associated 
Events.
So, in our ICU for a period of six months between April l2014 to September 2014,
the incidence of VAP was 4.24 per 1000 ventilator days.
Two events of Probable -VAP ventilator associated pneumonia were present in ETT C 
group and none in ETT SS group.
Therefore, the incidence of VAP in ETT C group was higher 4.44% compared 
to ETT SS group which was 0% because of the small incidence in both groups p value 
could not be calculated, shown in Table.8.
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TABLE.8: THE INCIDENCE OF VAP IN BOTH GROUPS
VENTILATOR
ASSOCIATED 
PNEUMONIA
TYPE OF ENDOTRACHEAL 
TUBE USED  TOTAL
PROBABLE-
VAP
0 2
(4,44%)
2
(2.3%)
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SECONDARY OUTCOMES
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SECONDARY OUTCOMES:
INCIDENCE OF VAE:
The overall incidence of VAE (VAC+IVAC+POSSIBLE VAP+PROBABLE VAP) was 
16.94 per 1000 ventilator days.
The above mentioned incidence was calculated using the formula given by CDC's 
National Healthcare Safety Network -NSHN for surveillance of ventilator associated 
events- VAE. 
INCIDENCE OF VAE = TOTAL NO EVENTS    X    1000 VENTILATOR DAYS
                                        TOTAL NO VENTILATOR DAYS
The VAEs summary,
•  Four events of Ventilator associated condition (VAC) were present in ETT SS 
group and none in ETT C group.
• One event of Infection related ventilator associated condition (IVAC) was present 
in both groups.
• Possible -VAP ventilator associated pneumonia was not present in either group.
• Two events of Probable -VAP ventilator associated pneumonia were present in 
ETT C group and none in ETT SS group. Shown in the following table.9.
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TABLE.9:
VAE INCIDENCE AMONG TWO GROUPS:
VENTILATOR
ASSOCIATED 
EVENTS-VAE
TYPE OF ENDOTRACHEAL 
TUBE USED
 TOTAL
ETT SS ETT C
VAC 4
(9.30%)
0 4
(4.55%)
IVAC 1
(2.32%)
1
(2.22%)
2
(2.27%)
POSSIBLE-
VAP
0 0 0
PROBABLE-
VAP
0 2
(4,44%)
2
(2.3%)
NO VAE 38
(88.37%)
42
(93.33%)
80
(90.85%)
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There were 5 Ventilator associated events – VAE in ETT SS group out of 42 patients vs 
3 Ventilator associated events – VAE in ETT C out of 45 patients which was not 
statistically significant with p-value of 0.41794, shown in table.10.
TABLE.10: NUMBER OF  VENTILATOR ASSOCIATED EVENTS IN EACH 
GROUP
TYPE OF TUBE USED p-value
ETT SS ETT C
VAE  5/43  = 11.6 % 3/45  =  6.6 % 0.41794 (proportion
test was used)
114
Figure below shows the incidence of VAE among ETT SS & ETT C groups:
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Figure showing the overall incidence of VAE in both groups
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DURATION OF MECHANICAL VENTILATION:
 The ETT SS group had statistically significant longer duration of mechanical 
ventilation 6.91  ±   5.68 days, compared to the ETT C group patients 3.89 ± 2.01 days, 
given in the table.11 below 
TABLE.11: DURATION OF MECHANICAL VENTILATION
Type of the tube 
used
ETT C ETT SS p-value
MV Days 3.89   ±  2.01 6.91  ±   5.68 0.0009
LENGTH OF ICU STAY;
The mean length of ICU stay was statistically significant as, ETT SS group 
patients had longer length of ICU stay 7.53   ±  6.29 days, compared to ETT C group 
patients 4.60  ±   2.28 days, with p-value of 0.006 given in table.12 
TABLE.12: LENGTH OF ICU STAY
Type of the tube 
used
ETT C ETT SS p-value
ICU Stay 4.60  ±   2.28  7.53   ±  6.29 0.0061
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LENGTH OFHOSPITAL STAY:
 
But, the mean length of hospital stay was comparable between two groups, ETT C 10.78
±  6.60 days vs ETT SS 12.95  ±   8.15 days, showing no statistically significant 
difference, as seen in the table.13 below.    
 TABLE.13:   LENGTH OFHOSPITAL STAY        
Typ e of the tube 
used
ETT C ETT SS p-value
Hospital Stay 10.78  ±   6.60 12.95  ±   8.15 0.127
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Figure representing the duration of mechanical ventilation,  ICU stay and hospital stay 
among ETT SS and ETT C:
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IN HOSPITAL MORTALITY:
While 21 patients died in the hospital in the ETT SS group, only 11 patients
died in the hospital in the ETT C group,  with p-value of 0.017, as shown in table.14 
below.
TABLE.14: IN HOSPITAL MORTALITY
Type of the tube 
used
ETT C ETT SS p-value
Mortality  11 21 0.017
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Figure showing in hospital mortality among two groups of patients:
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DISCUSSION
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Prevention of VAP needs a multipronged approach and we set out to see if 
the use of ETT SS as part of VAP bundle is associated with lesser incidence of VAP. 
With the change in the surveillance definition from the CDC, the future reporting will be
based on the new definition and we have studied with the new definition. 
With data already available in favor of ETT SS, we set out to see if this finding is 
applicable to our Indian set up.
We could not recruit the required number of patients due to time limit for 
submission of thesis. The interim analysis is underpowered, but is showing a trend 
favoring use of ETT SS. The study is ongoing and definite recommendations will be 
made on recruitment of the necessary number of patients. 
In our observational study the use of endo-tracheal tube subglottic drainage ETT 
SS was associated with reduced incidence of VAP in comparison with the standard endo-
tracheal tube ETT C.
The patients in ETT SS were older, had a higher sickness score, had more co-
morbid illnesses and were ventilated for a longer period. In spite of this they had lesser 
incidence of VAP. The mortality among this group was higher but this clearly is not 
related to pneumonia. The higher mortality may be related to the comorbidities and the 
higher sickness score. 
But, being an underpowered observational study, with inadequate sample size to 
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show statistically significant results, as results are obtained by interim analysis we 
decided to continue surveillance in our ICU and reserve the recommendation of its 
mandatory use in other ICUs, Operation Theaters, Emergency Department e.t.c, till the 
required sample size is achieved and results are re-analyzed.
The incidence of VAP in our ICU was 4.24 per 1000 ventilator days  which is 
comparable to the incidence reported in National Healthcare Safety Network facilities in
U.S.A (7).
This showed that in our ICU the VAP prevention strategies such as VAP BUNDLE
interventions are implemented effectively. 
The incidence of VAP is lesser than expected in our ICU  (8,9)., the VAP 
incidence calculated in all the ICUs put together in our hospital was about 40% the 
previous year  (quoted earlier-This cannot be compared) showing an improvement HAI 
awareness among the health-care personnel in our ICU and overall implementation and 
compliance to HAI prevention practices.
The overall incidence of ventilator associated events was not significantly 
different the two groups as evident in the interim analysis but, as the surveillance for 
VAE is being continued, it is only appropriate to wait till its completion and re-analyse 
the results prior to making a strong hypothesis.
As mentioned earlier in the previous section even-though the two study groups 
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were not comparable the in terms of demographics and clinical statuses. The ETT SS 
group patients were significantly older and sicker compared to ETT C group on ICU 
admission.
As significantly larger number patients in ETT SS group had co-morbid illnesses 
such as Hypertension, Ischemic Heart Disease, Chronic Liver Disease, Tuberculosis etc 
and they also had higher mean APACHE II scores compared to ETT C group, not all 
these factors were of statistical importance but, might be of clinical importance(35)  .
Moreover, the increased length of mechanical ventilation and longer ICU stay in t 
ETT SS group compared to ETT C can be explained by the fact that, more number of 
older and sicker patients were  in that group.
        So, longer time spent on ventilator, increased length of ICU stay associated with 
sicker and older patients of ETT SS group could have resulted in significantly  higher 
hospital mortality in this group.
It is encouraging to see that there is a trend towards lesser VAP with the use of 
ETT SS. This if confirmed after recruiting the necessary number of patients will be 
recommended to other areas of Hospitals for patients who will need mechanical 
ventilation in the ICU. 
Being an under-powered study no strong recommendation is made for the 
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regular use of ETT SS or subglottic secretion removal for VAP prevention at this point 
of time.
125
LIMITATIONS
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• The results of our study was obtained by interim analysis of data for the sake 
completion of post graduate dissertation.
• Being an under powered study no strong recommendation is made for the regular 
use of ETT SS or subglottic secretion removal for VAP prevention.
• This is an observational study limited to one ICU. A further study involving more 
centers will be more meaningful.
• The use of the new CDC VAP algorithm in immune-suppressed or patients with 
hematological disease with WBC counts in the extremes of spectrum is yet to be 
determined.
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CONCLUSION
•
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• We conclude at the end of our study that, the incidence of VAP- ventilator 
associated pneumonia showed a reduced trend with the use of ETT SS- Endo-
tracheal tube with subglottic suction drainage in comparison with standard endo-
tracheal tube ETT C.
• The overall incidence of ventilator associated events was not significantly 
different the two groups as evident in the interim analysis
• our study showed that in our ICU the vap prevention strategies such as Vap 
Bundle interventions are implemented effectively
• Strong recommendations regarding the use of ETT SS could not be made since, 
the sample size required for statistical significance was not achieved.
• The surveillance of VAP with the use of recent CDC algorithm will continue for 
the surveillance of VAP in our ICU  till the required sample size is achieved.
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section:1
Data collection sheet used in our study: page 1
INCIDENCE OF VAP/VAEs  ETT-SS (VS) ETT-C   IN SICU/AICU
S.NO-
PATIENT NAME:                                                                        AGE:       M/F
BRADMA
HOSPITAL NUMBER:
DURATION OF VENTILATION >48HRS: Y/N
DATE & TIME OF ICU ADMISSION:
PRIMARY DIAGNOSIS:
CHRONIC ILLNES:
APACHE II SCORE:
TYPE OF ENDOTRACHEAL TUBE:    ETT-SS /ETT-C
TIME AND DATE OF EXTUBATION:
MORTALITY IN ICU/WARD:
DATE &TIME OF ICU DISCHARGE:
DATE OF HOSPITAL DISCHARGE:
REINTUBATION DETAILS IF ANY :
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Data collection sheet used in  our study:page 2
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section:2
PATIENT INFORMATION SHEET
A  PROSPECTIVE OBSERVATIONAL STUDY COMPARING THE EFFECT OF   
ENDOTRACHEAL TUBE WITH SUBGLOTTIC SUCTION PORT VS STANDARD 
ENDOTRACHEAL TUBE ON INCIDENCE OF  VENTILATOR ASSOCIATED 
PNEUMONIA IN PATIENTS VENTILATED FOR >48 HRS IN ICU
This study, in which your relative is being asked to participate, is being conducted to 
assess the effectiveness of Endo-tracheal tube with subglottic suction port (ETT SS) in 
reducing pneumonia associated with ventilation.
 As part of the study, data will be collected from medical records.
Your relative will not have to undergo any special investigations in this study. 
This consent is for collecting some important details with regard to your relative such as,
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1. Type of Endotracheal tube used for intubation (the plastic tube used to give breaths 
from the ventilator or breathing machine),
2. Number of days on the ventilator (breathing machine) and ventilator settings,
3. Details regarding ICU & hospital stay,
 
4. Details regarding the germ growth from your lung secretions (Endotracheal Aspirate 
microbiology culture report),
5. Details regarding your relatives long term or previously known illness and reason for 
the admission into the ICU,
These details are collected for a research to find whether any significant advantage(s) 
is /are present in the use of ETT SS –Endotrachel Tube with subglottic suction port (this 
port allows periodical clearance of saliva which pools above the cuff which seals it 
around the windpipe) in comparison with ETT C-standard Endotracheal tube without 
suction port .
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The main purpose of this research is to find out whether the ETT SS usage offers 
considerable advantage in prevention of VAP- Ventilator Associated Pneumonia (a 
disease associated with the saliva dribbling past the breathing tube into the wind pipe 
resulting in lung infection).
As the results are just observed we will not interfere in any of the decisions made by 
ICU doctors regarding treatment, laboratory investigations etc.
I understand that my relative will not be offered any financial benefits because of 
participation in this study
The study details will be kept confidential in terms of personal information received 
from patients. Only the end results of the study will be published. The primary data 
collected will be kept with the primary investigator.
Consenting to be part of the study is purely voluntary. You can withdraw from the study 
at any time and no explanation needs to be offered regarding the same. 
The further course of treatment will follow the standard protocol and in no way you will 
be penalized for it. 
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Your relative is eligible for the standard care offered to all patients in CMC, Vellore. 
None of the study patients will be deprived of the available therapies. 
 
Any new information regarding the findings, if significant, will be notified to you. 
 
 In the event of any further queries about the study, risks and benefits at any point of the 
study, you can contact Dr. Sivakumar.G 0416 – 2282105 / 9842318899. 
Primary investigator-
Dr. Sivakumar. G,
Senior Resident,
Dept of Anesthesiology,
Christian Medical College -Vellore.
Ph. No.9842318899, 04162282105.
Email : sivadoc@gmail.com
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section:3
INFORMED CONSENT FORM :
 
1) Study Title: A Prospective Observational Study comparing the effect of 
Endotracheal Tube with Subglottic Suction Port vs standard Endotracheal tube 
on Incidence of Ventilator associated Pneumonia in patients ventilated for > 48 
hrs in ICU.
Patient’s Name: _________________________________________ 
Date of Birth / Age: ___________________________
Relatives name & Initials: __________________ 
Relationship:________________________________ 
 
 
Please mark in the boxes after reading, 
 
(i) I confirm that I have read and understood the information sheet dated _________ for
the above study and have had the opportunity to ask questions. [  ] 
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(ii) I understand that my relative’s participation in the study is voluntary and that I am 
free to withdraw at any time, without giving any reason, without my/his/her medical 
care or legal rights being affected. [  ] 
 
(iii) I understand that the cost of treatment and surgery I my relative is being charged is 
identical to other patients not participating in this study. I am aware that my relative 
will not be offered any monetary / other benefits. 
 
 (iv) I understand that the Sponsor of the clinical trial, others working on the Sponsor’s 
behalf, the Ethics Committee and the regulatory authorities will not need my permission 
to look at my health records both in respect of the current study and any further research
that may be conducted in relation to it, even if I withdraw from the trial. I agree to this 
access. [  ] 
 
(v) I understand that my relatives identity will not be revealed in any information 
released to third parties or published. [  ] 
 
(vi) I agree not to restrict the use of any data or results that arise from this study 
provided such a use is only for scientific purpose(s) [  ]  
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 (vii) I assent my relative to take part in the above study. [  ] 
 
 
 
 
 
 Signature (or Thumb impression) of the Legally Acceptable Representative 
Date: _____/_____/______ 
Signatory’s Name: _________________________________ 
 
Signature of the Investigator: ________________________ 
143
Date: _____/_____/______ 
Study Investigator’s Name: _________________________ 
 
Signature of the Witness: ___________________________ 
Date:_____/_____/_______ 
Name of the Witness: ______________________________ 
 
For Any Further clarifications contact: Dr. Sivakumar.G  at 0416 –2282105 / 
9842318899.email:sivadoc@gmail.com.
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Section:4
List of Antimicrobial Agents Eligible for IVAC, Possible and Probable VAP 
Antimicrobial Agent :
• AMIKACIN 
• AMPHOTERICIN B 
• AMPHOTERICIN B LIPOSOMAL 
• AMPICILLIN 
• AMPICILLIN/SULBACTAM 
• ANIDULAFUNGIN 
• AZITHROMYCIN 
• AZTREONAM 
• CASPOFUNGIN 
• CEFAZOLIN 
• CEFEPIME 
• CEFOTAXIME 
• CEFOTETAN 
• CEFOXITIN 
• CEFTAROLINE 
• CEFTAZIDIME 
• CEFTIZOXIME 
• CEFTRIAXONE 
• CEFUROXIME 
• CIPROFLOXACIN 
• CLARITHROMYCIN 
• CLINDAMYCIN 
• COLISTIMETHATE 
• DORIPENEM 
• DOXYCYCLINE 
• ERTAPENEM 
• FLUCONAZOLE 
• FOSFOMYCIN 
• GEMIFLOXACIN 
• GENTAMICIN 
• IMIPENEM/CILASTATIN 
• ITRACONAZOLE
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• LEVOFLOXACIN 
• LINEZOLID 
• MEROPENEM 
• METRONIDAZOLE 
• MICAFUNGIN 
• MINOCYCLINE 
• MOXIFLOXACIN 
• NAFCILLIN 
• OSELTAMIVIR 
• OXACILLIN 
• PENICILLIN G 
• PIPERACILLIN 
• PIPERACILLIN/TAZOBACTAM 
• POLYMYXIN B 
• POSACONAZOLE 
• QUINUPRISTIN/DALFOPRISTIN 
• RIFAMPIN 
• SULFAMETHOXAZOLE/TRIMETHOPRIM 
• SULFISOXAZOLE 
• TELAVANCIN 
• TELITHROMYCIN 
• TETRACYCLINE 
• TICARCILLIN/CLAVULANATE 
• TIGECYCLINE 
• TOBRAMYCIN 
• VANCOMYIN, intravenous only 
• VORICONAZOLE 
• ZANAMIVIR
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Section : 5 PATIENT DATA
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